SEC Form 4 · accession 0001127602-15-021307
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Jun 22, 2015
Accepted (ET)
Jun 24, 2015 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 22, 2015 | M | 3,750 | $4.73 | A | 149,894 | D | |
| Common StockF1 | Jun 22, 2015 | S | 3,750 | $16.00 | D | 146,144 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy)F1 | $4.73 | Jun 22, 2015 | M | 3,750 | D | Mar 1, 2013 | Mar 1, 2022 | Common Stock | 3,750 | 11,750 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2014.